CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2020	Mar. 31, 2020
Current assets:
Cash and cash equivalents	$ 43,326	$ 59,500
Short-term investments	201,320	109,055
Research and development incentives receivable	3,081	2,962
Prepaid expenses and other current assets	4,687	2,734
Total current assets	252,414	174,251
Property, plant and equipment, net	7,166	6,860
Research and development incentives receivable - long term	1,462
Restricted cash	1,636	1,636
Right-to-use asset-operating leases	5,830	4,425
Right-to-use asset-financing leases	45,736	46,925
Total assets	314,244	234,097
Current liabilities:
Accounts payable	2,374	3,434
Accrued expenses and other current liabilities	7,245	5,156
Operating lease liabilities, current	896	873
Financing lease liabilities, current	2,450	2,411
Total current liabilities	12,965	11,874
Long term debt, net of debt discount	9,827	9,801
Operating lease liabilities, non-current	5,177	3,737
Finance lease liabilities, non-current	24,885	24,967
Total liabilities	52,854	50,379
Commitments and contingencies (Note 12)
Stockholders' Equity
Common stock, $0.001 par value; 150,000,000 shares authorized as of September 30, 2020 and March 31, 2020; 40,312,272 and 36,668,743 shares issued and outstanding as of September 30, 2020 and March 31, 2020, respectively	40	37
Additional paid-in capital	411,847	296,961
Accumulated deficit	(149,886)	(112,298)
Accumulated other comprehensive loss	(611)	(982)
Total stockholders' equity	261,390	183,718
Total liabilities and stockholders' equity	$ 314,244	$ 234,097